Answers are grounded in this paper and cite their sources.
• This update provides recommendations for perioperative treatment of locally advanced oesophageal and OGJ adenocarcinoma. • Recent phase III data have demonstrated that perioperative ChT should be the preferred approach for most patients. • Updated recommendations are also provided for the use of immune checkpoint inhibitors in advanced squamous-cell carcinoma. • Algorithms for the management of locoregional oesophageal cancer and advanced squamous-cell carcinoma are provided. • Recommendations are based on available scientific data and the authors’ collective expert opinion.
No takes yet. Share an insight, caveat, or question.
Obermannová et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: